Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Genomics Innovation PCLBKK:BKGI +0.95%48 ROC (Joel Greenblatt) % is 50.51% as of Dec. 2025, which is 28% above its 10-year median of 39.48. GuruFocus rates BKK:BKGI with a GF Score™ of 48/100. The stock has 12 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks better than 77.73% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Bangkok Genomics Innovation PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 50.51%.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's ROC (Joel Greenblatt) % or its related term are showing as below:
BKK:BKGI'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 22.5 Med: 39.48 Max: 175.05
Current: 26.51
During the past 7 years, Bangkok Genomics Innovation PCL's highest ROC (Joel Greenblatt) % was 175.05%. The lowest was 22.50%. And the median was 39.48%.
BKK:BKGI's ROC (Joel Greenblatt) % is ranked better than 77.73% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.53
vs BKK:BKGI: 26.51
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BKGI vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 50.51% mean?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a ROC (Joel Greenblatt) % of 50.51% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is 28% above median its historical median of 39.48. Over the past decade, Bangkok Genomics Innovation PCL's ROC (Joel Greenblatt) % has ranged from 22.50 to 175.05. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #47 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 22.3%.
Is Bangkok Genomics Innovation PCL's ROC (Joel Greenblatt) % too high?
Bangkok Genomics Innovation PCL's current ROC (Joel Greenblatt) % of 50.51% is 28% above median its 10-year median of 39.48. Over the past 10 years, this metric has ranged from a low of 22.50 to a high of 175.05. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #47 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #47 out of 211 companies for ROC (Joel Greenblatt) %. This places Bangkok Genomics Innovation PCL in the top 22% of its industry — outperforming the majority of peers. Historically, Bangkok Genomics Innovation PCL's own ROC (Joel Greenblatt) % has ranged from 22.50 to 175.05 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bangkok Genomics Innovation PCL and its competitors. Bangkok Genomics Innovation PCL's current ROC (Joel Greenblatt) % is 50.51%, which is 28% above median its own 10-year median of 39.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current ROC (Joel Greenblatt) % of 50.51%. The current ROC (Joel Greenblatt) % is 50.51%, which is 28% above median its 10-year median of 39.48. Bangkok Genomics Innovation PCL's overall GF Score™ is 48/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current ROC (Joel Greenblatt) % is 50.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
48GF Score
Get the complete analysis for BKK:BKGI
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
